Aquestive Therapeutics Q2 2024 GAAP EPS $(0.03) Beats $(0.11) Estimate, Sales $20.099M Beat $12.380M Estimate
Portfolio Pulse from Benzinga Newsdesk
Aquestive Therapeutics (NASDAQ:AQST) reported Q2 2024 GAAP EPS of $(0.03), beating the $(0.11) estimate. Sales were $20.099M, surpassing the $12.380M estimate and showing a 51.79% increase from the same period last year.
August 06, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aquestive Therapeutics reported better-than-expected Q2 2024 results with EPS of $(0.03) beating the $(0.11) estimate and sales of $20.099M surpassing the $12.380M estimate. This represents a significant 51.79% increase in sales compared to the same period last year.
The significant beat on both EPS and sales estimates, along with a substantial year-over-year sales increase, is likely to positively impact AQST's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100